Sort   by:  
 Page size 
ProteomicsLC-MS data of IM95 gastric cancer cells following YAP degradation by bioPROTAC
In this study, through naïve nanobody phage library screening, we have identified multiple nanobodies against human YAP with high affinity and specificity. The YAP nanobody was then fused to the RING domain of RNF4, creating a bio-Proteolysis-Targeting Chimera (bioPROTAC) molecule capable of selecti...
ORGANISM(S): Homo sapiens (Human) 
2025-11-03 | PXD063726 | Pride
Gastric cancer cells Yap Bioprotac 
UnknownDevelopment of a targeted BioPROTAC degrader selective for misfolded SOD1.
Not available
S-EPMC12603324 | biostudies-literature
UnknownTargeted degradation of endogenous YAP by nanobody bioPROTAC inhibits tumor progression.
Not available
S-EPMC12549912 | biostudies-literature
ProteomicsUbiquitination site analysis of eGFP by DARPin-based bioPROTACs analysed by LC-MS-MS
We investigated design principles of DARPin-based bioPROTACs targeting the model substrate GS-eGFP (eGFP with an n-terminal tag, necessary for proteasomal unfolding). Using a highly active E3 ligase domain from CHIP and nine well-characterized DARPins, we evaluated their ability to induce proteasoma...
ORGANISM(S): Homo sapiens (Human) 
2025-06-05 | PXD063877 | Pride
Ubiquitination Darpin Bioprotac Egfp 
UnknownA TRIM21-based bioPROTAC highlights the therapeutic benefit of HuR degradation.
Not available
S-EPMC10625600 | biostudies-literature
ProteomicsTargeted protein degradation using E2 ubiquitin-conjugating enzymes
Proteins can be targeted for degradation by using engineered molecular conjugates to enhance their interaction with eukaryotic ubiquitination machinery. For instance, the fusion of an E3 ubiquitin ligase to a suitable target binding domain creates a biological ‘Proteolysis-Targeting Chimera’ (bioPRO...
ORGANISM(S): Homo sapiens (Human) 
2024-09-23 | PXD041225 | Pride
Bioprotac 
ProteomicsExamining the modality-dependent target specificity of bioPROTACs by analysing global proteome changes following mRNA-encoded or recombinant protein biodegrader delivery.
Proteolysis targeting chimeras (PROTACs) have surged in popularity as a drug modality owing to their ability to degrade pathogenic proteins. Despite their advantages over conventional inhibitors, PROTAC discovery still requires high-affinity warheads, but ligands for undruggable proteins are difficu...
ORGANISM(S): Homo sapiens (Human) 
2024-06-27 | PXD049388 | Pride
Recombinant protein Proteomics Lipid nanoparticle Protac Gtpase Mass spectrometry Ras Drug delivery Bioprotac Mrna Cytosolic delivery Kras 
UnknownTargeted degradation of KRAS and induction of bystander effects by a modular bioPROTAC.
Not available
S-EPMC12663003 | biostudies-literature
UnknownLipid-mediated intracellular delivery of recombinant bioPROTACs for the rapid degradation of undruggable proteins.
Not available
S-EPMC11237011 | biostudies-literature
UnknownTargeted protein degradation using chimeric human E2 ubiquitin-conjugating enzymes.
Not available
S-EPMC11415077 | biostudies-literature
Sort   by:  
 Page size